Kiniksa Pharmaceuticals, Ltd. (KNSA)

USD 21.77

(-1.98%)

Market Cap (In USD)

1.58 Billion

Revenue (In USD)

270.25 Million

Net Income (In USD)

14.08 Million

Avg. Volume

605.15 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
16.56-28.15
PE
-36.28
EPS
-0.6
Beta Value
0.348
ISIN
BMG5269C1010
CUSIP
G5269C101
CIK
1730430
Shares
72644235.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Sanj K. Patel
Employee Count
-
Website
https://www.kiniksa.com
Ipo Date
2018-05-25
Details
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

More Stocks